Subscribe to Search results

At an SNBTS medical and scientific committee meeting it was reported that there was "considerable demand" for interferon in Scotland "but, as yet, no 'ring fenced' money."

Published on:

At an SNBTS medical and scientific committee meeting Dr Aileen Keel "advised that 'ring fenced' funding for interferon treatment would not materialise."

Published on:

Ribavirin was licensed for distribution in the UK.

Published on:

Ribavirin had been available on a named patient basis prior to licensing.

Published on:

The Department of Health introduced a statutory obligation for the NHS to provide funding for NICE-recommended medicines and treatments from three months following approval.

Published on:

The CMO of England, Liam Donaldson, published Getting Ahead of the Curve, a strategy for infectious diseases. The strategy identified the high prevalence of Hepatitis C in England and announced a specific strategy to bring together actions to improve Hepatitis C awareness and treatment.

Published on:

The Hepatitis C Action Plan set out a framework for how to implement a treatment strategy. It identified that treatment services varied across different parts of the country and detailed a need for high-quality health services for the assessment and treatment of those with Hepatitis C

Published on:

The second phase of the Hepatitis C Action Plan was introduced in Scotland, which published the results of data gathering, showing that an insufficient number of people were being diagnosed and receiving antiviral treatment and that there were inequalities across Scotland in treatment.

Published on:

Scotland was cited by WHO as a "model country" in terms of its response to the Hepatitis C challenge.

Published on:

Strategic Framework and Action Plan for the Prevention and Control of Hepatitis C in Northern Ireland was published.

Published on:

NICE issued guidelines for treatment of Hepatitis C with sofosbuvir. This would normally lead to compliance within 3 months. However, NHS England requested that implementation be delayed until 31 July 2015. Four reasons were put forward for the delay.

Published on:

The Guardian published an article reporting that the Hepatitis C drug, sofosbuvir, had been delayed by the NHS due to its high cost.

Published on:

The day the Penrose Report was published, Prime Minister, David Cameron, announced "up to 25 million in 2015-16 to support any transitional arrangements to a better payments system."

Published on:

Jeremy Hunt, as the Secretary of State for Health, wrote to David Cameron, setting out three options for support to replace the existing Alliance House Organisations. One option he proposed was that the 2,500 people within "the infected blood cohort" who had not thus far had accelerated access to sofosbuvir-linked treatments should be funded to receive it.

Published on:

David Cameron did not indicate any interest in pursuing the option of accelerated Hepatitis C treatment.

Published on:

The NHS introduced an early access treatment programme for Hepatitis C for those with the greatest clinical need. This gave patients with decompensated cirrhosis access to sofosbuvir ahead of it being available in August 2015, as well as other new DAAs.

Published on:

Scotland introduced a policy of prioritising antiviral therapy for those with moderate to severe liver disease. The policy of prioritisation ended in 2018.

Published on:

Professor John Dillon, clinical lead for Hepatitis C in NHS Tayside, described the approach to treatment of Hepatitis C in Scotland.

Published on:

Funding for DAAs was provided through operational delivery networks across England. Each one was provided with a proportion of the budget for Hepatitis C treatment based on the estimated treatment figures for the area covered and the local prevalence of Hepatitis C.

Published on:

Professor Graham Foster explained the phases of NHS England's Hepatitis C elimination programme.

Published on: